Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
PCVX

PCVX - Vaxcyte, Inc. Stock Price, Fair Value and News

69.27USD-2.09 (-2.93%)Market Closed

Market Summary

PCVX
USD69.27-2.09
Market Closed
-2.93%

PCVX Alerts

  • 4 major insider sales recently.

PCVX Stock Price

View Fullscreen

PCVX RSI Chart

PCVX Valuation

Market Cap

7.8B

Price/Earnings (Trailing)

-17.77

Price/Sales (Trailing)

1.6K

Price/Free Cashflow

-18.3

PCVX Price/Sales (Trailing)

PCVX Profitability

Return on Equity

-22.02%

Return on Assets

-20.89%

Free Cashflow Yield

-5.47%

PCVX Fundamentals

PCVX Revenue

Revenue (TTM)

4.8M

Rev. Growth (Yr)

-99.3%

Rev. Growth (Qtr)

-99.6%

PCVX Earnings

Earnings (TTM)

-436.8M

Earnings Growth (Yr)

-57.16%

Earnings Growth (Qtr)

47.44%

Breaking Down PCVX Revenue

52 Week Range

45.5071.32
(Low)(High)

Last 7 days

-0.4%

Last 30 days

15.8%

Last 90 days

-3.4%

Trailing 12 Months

41.2%

How does PCVX drawdown profile look like?

PCVX Financial Health

Current Ratio

17.42

PCVX Investor Care

Shares Dilution (1Y)

16.10%

Diluted EPS (TTM)

-4.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
20232.4M4.2M5.7M4.8M
20221.7M2.1M1.9M1.9M
202102.5M1.8M1.9M
2020797.3K1.4M1.9M2.5M
2019000237.0K

Tracking the Latest Insider Buys and Sells of Vaxcyte, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 20, 2024
guggenhime andrew
acquired
42,800
5.35
8,000
president and cfo
May 20, 2024
guggenhime andrew
sold
-599,909
74.9886
-8,000
president and cfo
May 01, 2024
wassil jim
sold
-184,942
61.6473
-3,000
chief operating officer
May 01, 2024
eydelman mikhail
sold
-102,921
61.7404
-1,667
svp, gen counsel & corp sec
May 01, 2024
pickering grant
sold
-161,419
61.7046
-2,616
chief executive officer
May 01, 2024
eydelman mikhail
acquired
35,690
21.41
1,667
svp, gen counsel & corp sec
Apr 23, 2024
pickering grant
acquired
26,850
1.79
15,000
chief executive officer
Apr 23, 2024
pickering grant
sold
-928,845
61.923
-15,000
chief executive officer
Apr 18, 2024
guggenhime andrew
acquired
42,800
5.35
8,000
president and cfo
Apr 18, 2024
guggenhime andrew
sold
-490,199
61.2749
-8,000
president and cfo

1–10 of 50

Which funds bought or sold PCVX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 21, 2024
China Universal Asset Management Co., Ltd.
reduced
-50.58
-1,224,420
1,423,580
0.18%
May 16, 2024
COMERICA BANK
added
0.13
1,051,790
12,848,000
0.06%
May 16, 2024
Virtus Investment Advisers, Inc.
unchanged
-
17,511
217,089
0.16%
May 16, 2024
CASTLEARK MANAGEMENT LLC
reduced
-11.99
-228,346
5,125,980
0.21%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-77.57
-3,320,240
1,071,240
-%
May 16, 2024
Tidal Investments LLC
new
-
404,942
404,942
0.01%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
11.78
1,115,910
6,286,300
0.01%
May 15, 2024
Ghost Tree Capital, LLC
added
35.71
2,093,450
6,489,450
1.80%
May 15, 2024
ORBIMED ADVISORS LLC
reduced
-7.54
413,294
72,827,400
1.33%
May 15, 2024
SAMLYN CAPITAL, LLC
reduced
-8.06
1,679
20,676,000
0.35%

1–10 of 43

Are Funds Buying or Selling PCVX?

Are funds buying PCVX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PCVX
No. of Funds

Unveiling Vaxcyte, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
ra capital management, l.p.
9.99%
9,685,079
SC 13G/A
Feb 13, 2024
janus henderson group plc
7.3%
6,981,376
SC 13G/A
Feb 13, 2024
vanguard group inc
8.88%
8,452,371
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Jan 25, 2024
blackrock inc.
9.0%
8,575,238
SC 13G/A
Feb 14, 2023
ra capital management, l.p.
9.99%
8,153,559
SC 13G/A
Feb 10, 2023
tpg gp a, llc
1.5%
1,190,336
SC 13G/A
Feb 10, 2023
carlyle group inc.
2.6%
2,070,724
SC 13G/A
Feb 10, 2023
janus henderson group plc
7.6%
5,974,139
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A

Recent SEC filings of Vaxcyte, Inc.

View All Filings
Date Filed Form Type Document
May 22, 2024
4
Insider Trading
May 20, 2024
144
Notice of Insider Sale Intent
May 08, 2024
10-Q
Quarterly Report
May 08, 2024
8-K
Current Report
May 03, 2024
4
Insider Trading
May 03, 2024
4
Insider Trading
May 03, 2024
4
Insider Trading
May 01, 2024
144
Notice of Insider Sale Intent
May 01, 2024
144
Notice of Insider Sale Intent
May 01, 2024
144
Notice of Insider Sale Intent

Peers (Alternatives to Vaxcyte, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
62.6B
6.8B
56.39% 18.60%
-10.49
9.14
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.1B
2.0B
3.51% -21.34%
-57.48
9.53
75.20% 68.82%
14.5B
2.5B
-14.58% -16.90%
70.65
5.87
13.74% 186.89%
13.1B
3.8B
12.11% -10.56%
17.53
3.47
8.58% 129.81%
MID-CAP
5.5B
107.9M
16.79% 114.35%
-10.02
48.09
54.84% -28.31%
5.3B
524.1M
-8.42% -49.32%
-12.68
10.1
394.93% 39.61%
3.6B
251.0M
8.14% 7.06%
-12.31
14.53
73.58% -86.73%
3.1B
240.7M
5.18% -30.65%
-6.63
12.77
-1.03% -213.43%
2.6B
813.8M
-6.89% -38.06%
-1.5K
3.21
56.43% 98.83%
SMALL-CAP
2.2B
996.6M
286.24% 96.75%
-5.54
2.21
-26.66% 65.49%
1.9B
411.3M
6.95% 33.69%
29.29
4.64
60.38% -34.49%
482.9M
881.7K
19.87% 314.21%
-14.31
481.06
-77.61% 33.36%
293.3M
4.9M
12.97% 42.93%
-2.35
60.27
-54.97% 48.23%
19.2M
2.1M
25.28% 144.97%
-0.83
7.61
-13.45% 69.54%

Vaxcyte, Inc. News

Latest updates
Defense World35 hours ago
Yahoo Canada Shine On19 May 202401:46 pm

Vaxcyte, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q42020Q32020Q22020Q12019Q4
Revenue-100.0%-7.001,6402,4646549251576901609082993783267871,036329-
Operating Expenses-41.8%114,472196,676113,02687,14771,19286,57358,57747,88639,22129,84626,95123,73019,45321,30821,22427,59615,837
  S&GA Expenses-100.0%-17,52715,60514,45613,11211,95210,8989,4177,5436,7726,5236,0794,7924,8983,0463,2812,456
  R&D Expenses-9.2%94,587104,15097,42172,69158,08051,62647,67938,46931,67823,07420,42817,65114,66116,41018,17824,31513,381
Interest Expenses--------2.00---7.00---7.007.00
Net Income47.4%-95,020-180,801-92,664-68,339-60,462-78,050-57,917-48,532-38,986-28,563-26,615-23,679-20,737-21,018-20,320-27,142-14,621
Net Income Margin-8.6%-91.68*-84.43*-52.71*-63.05*-100.99*-115.71*-90.86*-69.37*-67.53*-52.37*-51.54*-34.29*-----
Free Cashflow-22.9%-164,802-134,064-64,887-60,602-53,299-66,368-39,391-40,064-30,622-52,475-30,134-30,888-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Assets48.5%2,0911,4081,4961,5031,0081,00641241240332435435838239340441666.00
  Current Assets38.4%1,5171,0961,2951,31084194337036434225630330232538940141362.00
    Cash Equivalents54.1%61339754553138083527923920370.0011315220038639741059.00
  Net PPE6.5%85.0080.0011.0016.0015.0010.0010.0010.0010.008.007.006.005.003.003.003.003.00
Liabilities-35.9%10716793.0069.0063.0053.0053.0045.0043.0040.0048.0041.0055.0047.0040.0033.0012.00
  Current Liabilities-40.1%87.0014586.0060.0053.0041.0039.0030.0027.0029.0047.0041.0055.0047.0040.0033.0011.00
Shareholder's Equity59.9%1,9841,2401,4031,433945954359367360284306317327346364383-
  Retained Earnings-10.3%-1,019-924-743-650-582-522-444-386-337-298-270-243-219-198-177-156-109
  Additional Paid-In Capital38.6%3,0002,1652,1482,0871,5271,4768047546985835765605475445425403.00
Shares Outstanding14.0%10995.0095.0094.0081.0079.0062.0061.0058.0052.0052.0052.00-----
Float----4,100---1,100---789---950-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Cashflow From Operations-23.5%-159,124-128,810-57,548-62,742-47,690-65,221-38,548-39,126-27,702-51,093-28,415-28,680-13,205-10,768-13,055-9,172-13,633-14,406-9,458--
  Share Based Compensation32.1%17,62913,34813,22012,5449,6487,0096,6485,8944,0993,1582,9372,7691,8651,9351,8381,289372375265--
Cashflow From Investing-3139.1%-451,073-13,92622,280-333,564-448,101-35,95234,70626,16549,66682.00-18,469-20,530-173,391-72221.00-55.00-349-953-60.00--
Cashflow From Financing29815.8%818,1962,73548,550546,96641,562656,63344,01749,878111,0198,7547,59995648755536.00264,482109,79741,352368--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

PCVX Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 94,587$ 58,080
General and administrative19,88513,112
Total operating expenses114,47271,192
Loss from operations(114,472)(71,192)
Other income (expense), net:  
Interest income21,66610,393
Grant income126654
Realized gains on marketable securities220
Foreign currency transaction losses(2,362)(317)
Total other income, net19,45210,730
Net loss$ (95,020)$ (60,462)
Net loss per share, basic (in dollars per share)$ (0.85)$ (0.70)
Net loss per share, diluted (in dollars per share)$ (0.85)$ (0.70)
Weighted-average shares outstanding, basic (in shares)111,690,95186,206,817
Weighted-average shares outstanding, diluted (in shares)111,690,95186,206,817

PCVX Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 611,512$ 397,451
Short-term investments875,006682,776
Prepaid expenses and other current assets30,55415,727
Total current assets1,517,0721,095,954
Property and equipment, net84,83579,626
Operating lease right-of-use assets28,90530,997
Long-term investments413,247162,675
Restricted cash1,1031,103
Other assets46,14337,562
Total noncurrent assets574,233311,963
Total assets2,091,3051,407,917
Current liabilities:  
Accounts payable21,71714,587
Accrued compensation3,08811,056
Accrued manufacturing expenses92652,767
Accrued expenses54,17159,815
Operating lease liabilities — current7,2027,113
Total current liabilities87,104145,338
Operating lease liabilities — long-term20,21822,111
Total liabilities107,322167,449
Commitments and contingencies
Stockholders' Equity  
Preferred stock, $0.001 par value — 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 202300
Common stock, $0.001 par value — 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 108,755,731 and 95,364,831 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively11298
Additional paid-in capital3,000,3942,164,583
Accumulated other comprehensive gain2,889179
Accumulated deficit(1,019,412)(924,392)
Total stockholders' equity1,983,9831,240,468
Total liabilities and stockholders' equity$ 2,091,305$ 1,407,917
PCVX
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
 CEO
 WEBSITEhttps://vaxcyte.com
 INDUSTRYBiotechnology
 EMPLOYEES158

Vaxcyte, Inc. Frequently Asked Questions


What is the ticker symbol for Vaxcyte, Inc.? What does PCVX stand for in stocks?

PCVX is the stock ticker symbol of Vaxcyte, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaxcyte, Inc. (PCVX)?

As of Wed May 22 2024, market cap of Vaxcyte, Inc. is 7.76 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PCVX stock?

You can check PCVX's fair value in chart for subscribers.

What is the fair value of PCVX stock?

You can check PCVX's fair value in chart for subscribers. The fair value of Vaxcyte, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vaxcyte, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PCVX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vaxcyte, Inc. a good stock to buy?

The fair value guage provides a quick view whether PCVX is over valued or under valued. Whether Vaxcyte, Inc. is cheap or expensive depends on the assumptions which impact Vaxcyte, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PCVX.

What is Vaxcyte, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 22 2024, PCVX's PE ratio (Price to Earnings) is -17.77 and Price to Sales (PS) ratio is 1.63 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PCVX PE ratio will change depending on the future growth rate expectations of investors.